Introduction
Carbohydrates are the most abundantly expressed auto-antigens on tumor cells and conseqeuntly they are precieved as viable targets for immunotherapy. Examples of tumorassociated carbohydrate antigens include GD2, GD3, fucosyl GMl, Globo H, STn and the neolactoseries antigens sialyl-Lewis x (sLex), sialyl-Lewis a (sLea) and Lewis Y (LeY). In clinical trials, carbohydrate vaccine formulations induce humoral responses that are considered beneficial, because these responses are associated with better prognosis for the patients. While pure carbohydrate antigens elicit diminished immune responses because of their T cell independent nature, conjugate vaccine technology has overcome some of the limitations of carbohydrates as vaccine antigens because of the T-dependent (TD) help conferred by the protein (1, 2) . Conjugation of carbohydrates to a carrier protein that elicit carrier-specific T-and B cell responses does not necessarily enhance carbohydrate immunogenicity (3) . In the case of responses to conjugated carbohydrate, it can be speculated that the type of T helper cells (Thl or Th2) can modulate the amount and isotype switch of the anti-carbohydrate IgG. Despite their promise, carbohydrate-conjugates induce responses that are often deficient in many respects, including the lack of induction of the Thl associated murine IgG2a isotype (4) . In this regard, a role for IFNy and lymphocytes in initial tumor development has been documented and more specifically a Thl-and CTL-mediated response with production of IFNy is thought to be necessary for the induction of antitumor immunity. Carbohydrate-conjugates are characteristic of traditional vaccines inducing Th2-biased immune responses with a high titer of antibodies and almost without a significant induction of cell-mediated immunity against the respective antigen. Consequently, new formulations or alternative ways to augment carbohydrate reactive immune responses are being evaluated. We are demonstrating that peptides mimicking breast associated neolactoseries antigens are capable of activating carbohydrate specific cellular immune responses (manuscript #1) that limit tumor growth in vivo. Thus, carbohydrate-mimicking peptides represent a new and very promising tool to increase the efficiency of the immune response to carbohydrates.
Body
During the initial fiinding period we have focused on characterizing the immune response parameters upon vaccination with peptide mimetics. This was specific aim 1. We have published 1 paper and preparing another manuscript for submission. The basis of the second paper was presented at the 6* International symposium on Predictive Oncology and Intervention Strategies held in Paris France and was a winner (1st place) of the Symposium Presidents' Award for Scientific Excellence (;http://www.cancerprev.org/Meetings/2002/Awards\ However, we deviated to some extent fi-om our initial tasks to fiirther validate the use of peptide mimetics to augment the response to tumor cells.
Task 1. Establish murine breast tumor model (months 1-3).
The purpose of this Task was to develop a model system with two objectives. One, to use a cell type relevant to Breast cancer. The other to use a cell line that expresses relevant neolactoseries carbohydrate stiiictures. We had established by FACS analysis that murine 4T1 cells do not express LeY nor sLex or sLea. This cell line (H2-d) is highly metastatic and is weakly immunogenic. In Task 1 we planned to transfect murine 4T1 cells with fiicosyltransferases. However, in our present studies we used the murine cell line Meth A (H2-d) as a model. Meth A is a Methylcholanthrene-induced sarcoma of BALB/c origin. We identified a clone by FACS sorting with the anti-extended sLex sti-ucture reactive FH6 antibody. Sorted cells were passed as an ascitic tumor. It was thought that manyproof of principle experiments could be conducted with this cell line early on. In our first year we established that immunization with a peptide mimetic of core structures of the neolactoseries structure that reacts with an anti-LeY monoclonal antibody and reacts with an anti-extended sLex reactive monoclonal elicits a cellular response to Meth A cells. Peptide presentation can be of the form of a multiple peptide or encoded into a DNA plasmid. We are now beginning the transfection experiments with 4T1.
Peptide mimetics activate cellular responses to Model carbohydrate expressing cell line (manuscript #1).
The metastatic potential of some tumor cells is associated with the expression of the sLex sLea as they are Ugands for selectins. We have shown that peptide mimetics of these antigens can potentiate IgG2a antibodies, which is associated with a Thl type cellular response. As Lselectin is preferentially expressed on CD4+ Thl and CD8+ T cell populations, specific induction of these phenotypes could augment a response to L-selectin ligand expressing tumor cells. We demonstrated that immunization with a multiple antigen peptide (MAP) mimetic of sugar constituents of neolactoseries antigens induces a MHC dependent peptide specific cellular response that triggers IFNy production upon peptide stimulation, correlating IgG2a induction upon mimetic immunization. Surprisingly, T lymphocytes fi-om peptide immunized animals were activated in vitro by sLex, also triggering IFNy production in a MHC dependent manner. Stimulation by peptide or carbohydrate resulted in loss of L-selectin on CD4+ T cells confirming a Thl phenotype. We also observed an enhancement in CTL activity in vitro against sLex expressing Meth A cells using effector cells fi-om Meth A primed/peptide boosted animals. CTL activity was inhibited by both anti-MHC Class I and anti-L-selectin antibodies. These results fiorther support a role for L-selectin in tumor rejection along with the engagement by T cell receptor for most likely processed tumor-associated glycopeptides. Peptide mimetics therefore appear promising to mediate carbohydrate reactive cellular responses.
BALB/c female mice were immunized with a multivalent antigen peptide (MAP) called 106 MAP with the 106 sequence GGIYWRYDIYWRYDIYWRYD and splenocytes were collected seven days after the last immunization. Cell proliferation was assessed in the presence of the peptide (Fig lA) , with purified T lymphocytes alone and after addition of MMC inactivated antigen presenting cells (APCs) (Fig. IB) . The results indicate that proliferation is APC dependent. Proliferation of the peptide specific T lymphocytes was not observed in the absence of APCs. Proliferation was inhibited by the addition of anti-Class II, and to a lesser extent with antiClass I antibodies (Fig. IC) . The addition of anti-CDl antibody inhibited proUferation to almost the same extent as addition of anti-Class I antibody (manuscript #1). Therefore, the 106 peptide might be presented in multiple ways to T cells. IFN-y production was found to be peptide specific (Fig. ID) [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] and Task 4 (months 18-36) in that we have started to look at priming and boosting and challenge experiments. We will continue to assess a role played by GM-CSF and will follow through with a complete assessment of the subtasks as described in the proposal using 4T1 cells expressing neolactoseries antigens as they become available.
As we have characterized peptide 106 encoded DNA (5) we immunized groups of mice with the DNA version of 911 peptide (D911 with plasmid design described in our original proposal) and then boosted them, after three weeks, with DNA (D911/D911), or BSA-conjugated peptide (D911/Pconj911). Analysis of humoral response by ELISA against LeY antigen ( Fig.  2A,B) showed that DNA immunization primes for both IgM and IgG reactive antibodies. Either DNA or BSA-conjugated peptide boost similar levels of IgM and IgG. We examined binding of IgG portion of generated sera to MCF-7 and A1953 cell lines. As shown in figure 3 (A,B) we did not detect significant differences in binding between sera. A CDC assay was also performed, with an overall cytotoxicity of about 30%, and did not show any preference for DNA or peptide conjugate immunized serum over MAP (data not shown). 
Mimotopes are superior immunogens than carbohydrates
A closer look at the above data revealed to us that mimotope immunization might induce a type of memory for generation of serum IgM, which is long lasting. To examine this issue we primed mice with 911 MAP and then boosted them with sLex (sialyl Lewis "-PAA). Serum reactivity was then checked against sLex. As shown in figure 4 , 911 peptide primes for IgM-sLex reactive Abs. Immunization with sLex boosts the response and it lasts longer than it does in immunization with sugar only. Sugar boosted the response and stabilized it for a longer time period. The data suggest that there is a priming effect, with peptide immunization, for generation of cross-reactive IgM and the generated IgM is longer lasting. We also analyzed the cross-reactive IgG response during the course of experiments, as we reported before we also detected a prime and boost effect for IgG of low titer (data not shown). The results suggest that despite the induction of a state of tolerance in carbohydrate immunization, mimotope immunization induce a type of memory for the IgM portion of the serum, priming for later sugar immunization. 
Therapeutic peptide immunization induces tumor regression
In Task 2 we had described studies using IL-12 encoded DNA to augment the potential Thl and possible CTL response. We had decided to try a series of pilot experiments using recombinant IL-12 first. To study the outcome of peptide immunization on the growth of soUd tumors in vivo, we evaluated the antitumor cellular response on established Meth A tumors. BALB/c females were inoculated sub-cutaneously with 5 X 10' Meth A cells and seven days later treatment was started with the peptide injected intraperitionealy (3 times at 4-5-day intervals). As shown in Figure 5A , immunization moderately affected Meth A sarcoma growth, as 6 mice out of 11 immunized were cured. Treatment of animals with IL-12 following peptide immunization, intending to enhance the immune response, was successful as it mediated the complete eradication of estabUshed tumors (Fig. 5B) . Treatment of tumor-bearing mice with only IL-12 did not affect tumor growth (Fig. 5C ). We further determined that Peptide/IL-12 combination therapy is highly effective even in lower doses of IL-12, as 100 ug of daily IL-12 treatment in combining therapy, but not alone, eradicated tumors in 5 mice of five challenged (Fig. 5D,E) . The time of the beginning of immunization and the size of tumor at this time apparently affect the efficacy of immunization. With immunizations started at day 14 or later or treating tumors with mean diameter of larger than 7 mm the efficacy of immunization dropped significantly (Fig. 5F ). 
Peptide immunization leads to an increase in T-cell population and IL-12 responsiveness of T cells
Next we asked if the T cell population was increased after immunization with peptide. We used flow cytometry to examine the expression of CD3, CD4, CDS and NK marker (DX5) on the surface of freshly isolated splenocytes. As shown in Figure 6A , the proportion of CD4+ and CD8+ T cells increased in immunized/cured mice compared with non-immunized/tumorbearing animals. We did not detect any difference between groups of mice regarding NK cell population using the DX5 antibody. To determine whether this population could be stimulated by IL-12, an IL-12 responsiveness test was performed on the T-cell population. Individual mice from nonimmunized/tumor-bearing, and immunized/cured groups were sacked and T-cells purified using nylon wool followed by depletion of NK cells and a subsequent positive selection for Thy 1.2 using MACS. Purity of T cells was more than 97% as assessed by expression of CDS molecule by FACS. Purified T cells were seeded and stimulated with various concentrations of IL-12 and induction of IL-12 responsiveness was determined by measuring IFN-y production. Figure 6B shows that T cells from peptide-immunized animals produced IFN-y upon stimulation with IL-12.
As it is clear from our data regarding tumor challenge and peptide boost we had a prime and boost effect, we thought to magnify our priming by immunization with inactivated cells. In this case we replaced our first peptide immunization with inactivated Meth A-cell immunization. Tumor-bearing mice seven days after tumor inoculation first were immunized with attenuated cells (lOVmouse, i.p.), followed by a combination of peptide/IL-12 as explained before.
Unexpectedly, this immunization regimen was less efficient as we recorded 3-4 escaped mice out of 12 in each separate experiment. The data again suggested that peptide immunization is efficacious but it should be done early on, as large tumors are hard to treat. Taking advantage of other effector cells, we further tried to stimulate eradication of tumors in immunized/tumorbearing animals by treating them with Cyclophosphamide (Cy). Cy injected littermates were immimized with the peptide mimetic after 7 days followed by 5 doses of IL-12. We speculated that using this regimen, we might activate effector cells, which may cooperate with T cells in eradicating tumors of larger size. Following Cy and peptide/IL-12 therapy a clear tumor regression was marked in two thirds of the cases (data not shown).
To further understand what cell population was in charge of such distinct tumor regression, we isolated splenocytes and stained cell surface markers by flow cytometry. As shown in Figure 7 , it appears T cells may be the major effector population. 
Peptide-mediated tumor-growth suppression is dependent on cellular responses
To determine whether the anti-tumor activity mediated by peptide/IL-12 therapy is dependent on a cellular adaptive immune response we evaluated our therapeutic strategy in nude mice. BALB/c-nu/nu mice bearing Meth A tumors were immunized with the peptide followed by IL-12 treatment (Fig. 8) . Combined peptide/IL-12 therapy had no effect on tumor growth of nude mice, indicating the dependence of mediated tumor mice.
Days after tumor inoculation
regression on T cells. We prepared histologic sections of the tumor site and surrounding areas from non-immunized and immunized littermates. As shown in Figure 9 , in confrast to nonimmunized tumor-bearing mice, we detected lymphocytes in periphery infilfrating into tumor mass of immunized mice ( 
Adoptive transfer of splenocytes stimulates eradication of tumors in nude mice
To further confirm a role played by T cells activated by the peptide mimotope, nude mice were transplanted with Meth A cells and injected ip with fi-esh splenocytes, isolated fi:om cured mice, 10 days later (Fig 10) . Immune cells transferred had a dramatic effect on tumor size as by day 15 after transfer tumor was eradicated completely in all four mice tested. In a follow-up study splenocytes were depleted from B ___ Days after tumor inoculation
Figure 11. Adoptive therapy of established tumors is dependent on CD8+ cells but not CD4+ T cells. Solid tumors were established in nude mice and at day 7 enriched splenocytes were transferred ip. For enrichment, splenocytes were passed through nylon wool after which the percentage ofCD19+ cells remained were less than 7%. The percentage ofCD8+ and CD4+ cells in CD4+ and CD8+ enriched population was less than 10%.

Expression of FH-6-reactive antigen on escaped tumor variants
To examine a possible change in phenotype of tumors in mice that escaped our therapy, tumor masses were isolated from uncured mice and stained with FH-6 antibody. As illusfrated in figure 9 , tumor cells that did not respond to therapy lost the expression of the extended sLex on the surface. However, some individuals do not respond well to peptide or no strong immune response initiates after tumor transplant. IL-12 or Cy treatment later enhances T-cell responses and clears the tumors, but in those mice that tumor continued to grow the tumor phenotype might be changed to escape immunity. 
Peptide 106 boosting can affect Meth A directed CTL.
While Meth A cell priming and boosting can lead to CTL activity against Meth A cells, peptide boosting increased tiie level of cytotoxicity against Meth A cells to a statistically significant level as compared with cytotoxicity against P815 cells as conti-ol target indicating a cross-reactive nature between peptide and tumor specific CTL responses. CTL activity was inhibited by the addition of either anti-Class I or anti-L-selectin antibody. However, we could not block CTL activity by the sLex reactive antibody FH6. It is possible that FH6 binds to a subtype of sLeX carbohydrate epitopes that do not always fiinction as ligands for Lselectin just like it defines a subset that does not bind to E-selectin (6) . This is also similar to that found for the antibody MECA 79 which binds to a subset of sulfated sLex different than that of L-selectin (7). L-selectin is known to bind to a variety of carbohydrates expressed on glycoproteins (8, 9) It is possible that L-selectin functions as an auxiliary molecule (10) and by itself is not sufficient to mediate CTL killing, but requires engagement of antigen specific TCR (11) . NK cells on the other hand also express L-selectin and NK cells appear to mediate cytolysis of tumor cells that express high levels of sLex (12) . However, direct evidence that fiiscosylated selectin ligands play a role in tumor rejection is still lacking.
Immunization with Peptide 106 along with IL-12 can eradicate established tumors.
As it was expected, immunization with 106 MAP moderately inhibited tumor growth. It was shown that vaccination with inactivated Meth A cells had no effect on tumor growth, suggesting a superiority of 106 peptide vaccine to a cell-based one in this model. Our data proposes that immvinization with only 106 peptide is not sufficient for induction of a state of reliable immunity to eradicate tumor. IL-12 is known to exhibit potent anti-tumor activity in a number of murine tumor models. Further treatment of peptide immunized mice with IL-12 or a combination of Cy and IL-12 considerably helped in stimulating eradication of tumor.
6. Both types of T cells seem to play a role in tumor cell erradication. Our data shows that there is a proportional increase in the CD4+ and CD8+ T cells among splenocytes of treated mice compared to tumor-bearing mice. We did not observe any differences between splenocytes of these two groups of mice regarding the expression of NK cell marker DX5. Therefore, we propose that 106 immunization induces a population of Thl and CTLs with production of IFNy, and that IL-12 helps out with expanding the T cell population and activating IFNy production. As resting T cells do not express IL-12 receptor and IL-12 responsiveness is induced after TCR stimulation, purified T cells were stimulated with IL-12 in vitro. The data indicate that in tumor-bearing animals T cells were not sensitized with tumor antigens, while peptide immunization induced T-cell responsiveness to IL-12.
7. The designed 106 sequence is superior to the 911 sequence as a means to inhibit tumor growth. DNA immunization with the 911 sequence did not mediate tumor growth inhibit even with the addition of IL-12.
Reportable Outcomes
One manuscript was published and another is in preparation. We have presented the results to be included in the manuscript in preparation at a conference in which it was judged meritoriously. We have shown that immunization with peptide 106 induces cellular responses that are not achievable by immunization with carbohydrate alone. Although cellular responses generated by the peptide mimotope may enhance CTL induction, vaccination with peptide alone appears not to be completely sufficient in the effector phase when challenged with a very high tumor burden (13) . Our CTL data using effectors from peptide only immxmized mice on Meth A cells as targets confirm this fact with marginal CTL activity observed.
Our results are very narrow with regards to the breadth of carbohydrate directed cellular responses. However, constituents of sLex and sLea are proposed to be influential to the metastatic properties of a variety of human tumor cells. Consequently, fiirther efforts to optimize and isolate the carbohydrate moieties associated with presented glycopeptides may facilitate vaccine applications for eradication of metastatic lesions by both antibody dependent lysis and cellular responses. This possibility has yet to be proved with the appropriate models but suggests that for certain carbohydrate antigens like sLex and sLea, peptide mimetics might augment cellular responses other than delayed-type hypersensitivity like responses in fiiture vaccine appUcations. The generated data support the idea of successfiil treatment of estabUshed tumors. As a challenge model we used BALB/c Meth A sarcoma, as we know that respective carbohydrates are expressed on the surface of this cell line.
Conclusions:
Defining new targets for designing effective and broad-based vaccines is considered crucial for the immunotherapy of solid tumors. Carbohydrates are abundantly expressed on the surface of malignant cells and induction and enhancement of a cell-mediated immune response toward 12 
Introduction
Tumor-associated carbohydrate antigens are con-elated with metastatic phenotype and poor survival in epithelial malignancies of different origins. The expression of the neolactoseries antigens represented by sialyl-Lewis x (sLex), Lewis x (Lex) and Lewis Y (LeY) are increased significantly on a variety of carcinomas (1-6), with sLex and sialyl-Lewis a (sLea) also reported to be expressed on melanoma cells (7). Early studies indicated a possible relationship between metastatic properties of tumor cells and the expression of these antigens leading to tumor cell dissemination (8) (9) (10) (11) ). An inhibitory effect on the establishment and growth of metastatic colonies of tumor cells expressing these antigens has been noted when anti-sLea or anti-sLex antibody was administered to mice in a pancreatic tumor murine model (12) . A cellular role played by L-selectin expressed on lymphocytes has also been noted in that anti-L-selectin antibody (Mell 4) can influence cytotoxic T Lymphocyte (CTL) sensitization and metastatic colony formation (13) , and Mel 14 can inhibit CTL activity of effector cells in vitro derived from immunization with selectin-ligand expressing cells (14) . These results strongly suggest that blood-borne tumor cells may utilize these antigens with selectin molecules when tumor cells adhere to the endothelia at metastatic sites (1, 12, (15) (16) (17) . Over-expression of selectin ligands on tumor cells are also targeted by NK cells (18) . Consequently, targeting these antigens may thwart tumor cell dissemination. We have recently shown that peptide mimetics of selectin ligands can induce a humoral response that targeted sLex in a murine tumor model facilitating tumor growth inhibition (19 (27) , we were also interested in whether mimeotope immunization could augment a CTL response to fibrosarcoma Meth A cells. We observed that peptide immunization promotes a specific cellular response with IFN-y production upon activation of splenocytes and T lymphocytes with immunizing peptide or with sLex and its homologue Lex. More importantly, we observed that immunization with peptide mimetic facilitated a specific cellular response to Meth A cells. Peptide boosting of mice primed with sLex-expressing Meth A cells enhanced the Meth A directed in vitro CTL activity. This activity was blocked not only by anti-MHC class I but also by anti-Lselectin antibody This latter observation parallels other studies describing a role for L-selectin in T cell-mediated rejection of cells that express its ligands, such as sLex (14) . The possibility of boosting lymphocyte subsets that cross-react with tumor cells that express L-selectin ligands opens new perspectives in designing cancer vaccines for further reducing micrometastases. sLex-expressing Meth A cells were selected by sorting of positive cells with anti-sLex FH-6 antibody from an original Meth A cell line and were 100% sLex+ upon prolonged culture. Meth A cells were repeatedly passed in vitro to decrease their tumorgenicity. Mice were immunized i.p. with 3X10^ of these cells. Non-tumor bearing mice were used for analysis or for further experiments.
Methods
Immunization of animals
Antibodies
All antibodies were purchased from PharMingen (San Diego ■ CA). Anti mouse l-A^ (AMS 32.1), H-2K'' (SF1-1.1) and CDId (1B1), and their lgG2a and lgG2b isotype controls were first dialyzed in PBS buffer and then used in the proliferation cultures. For fluorescent staining of the splenocytes we used biotinylated rat anti-mouse anti-CD62L (anti-L-selectin Mel-14) and its isotype control lgG2a; anti-CD4-FITC (L3T4) and its isotype control lgG2b-FITC.
Flow cytometry
Fresh or in vitro stimulated splenocytes were blocked before staining with PBS containing 1% BSA and 1% rat serum for 10 mm at 4°C. Cells were subsequently stained with rat anti-mouse mAb labeled with biotin, FITC or phycoerythrin Appropriate rat isotype controls were used to set up background fluorescence. Streptavidin-FITC or avidinphycoerythrin (Sigma, St Louis, MO) were used after biotin-labeled antibodies, as required. Acquisition of data was performed immediately after staining by using the FACScan analyzer and analysis performed by CellQuest software (both from Becton Dickinson Immunocytometry Systems Mansfield, MA).
In vitro proliferation assays
Spleens were aseptically removed from each group Splenocytes were harvested from spleens, and isolated as the responder cells by lysis of erythrocytes and consequent washing several times with fresh media. Prepared responder cells were used for detection of cell proliferation, as described (28, 29) . Briefly cells (2.5xlo5/well) were cultured in flatbottom 96-well plates and incubated with MAP, carbohydrates ovalbumin (OVA) or media only After 3 days of incubation' 1 HCI of pH]thymidine was added to each well and cells were incubated for an additional 16-18 h. Cultures were then harvested and radioactive emission counted on a Betaplate liquid scintillation counter (EG & G Wallac, Turku, Finland).
Proliferation assay was also performed using CellTiter 96 Aqueous One Solution (Promega. Madison, Wl) based on the manufacturer's instructions. Cell culture was exactly performed as above and at the third day of incubation the provided solution was added to each well. Plates were incubated for an additional 1-2 h in a humidified 5% CO, incubator at 37°C. Absorbency was measured immediately at 490 nm using a 96-well plate reader (Spectra Ruor; Tecan Tnangle Park, NC) as a measure for cell proliferation.
For detection of cell proliferation in T lymphocyte-enriched populations, a single-cell suspension of isolated splenocytes was depleted of B cells by positive selection after incubation with pan-B (B220) magnetic beads (Dynal, Oslo, Norway) at 4°C, for 30 min. To separate adherent from non-adherent cells, the B cell-depleted population was resuspended in RPMI media with 20% FBS and incubated for two consecutive adherence periods of 1 h each, at 37°C in humidified atmosphere with 5% CO2. T lymphocytes were recovered and washed 3 times with RPMI/10% FBS and used in cell proliferation assays with or without mitomycin C (MMC)-treated antigen-presenting cells (APC). Adherent cells were recovered separately, treated with MMC (100 Hg/ml in RPMI supplemented with 10% FBS, for 40 min at 37°C) and used as APC in proliferation of purified T lymphocytes at 10% ratio. Purified T cell populations, checked by FACS analysis, were assessed as >95% CD3+, with no CD19+ cells, and used in cell proliferation assays as explained above. Medium used for the proliferation assays was RPMI 1640 (Life Technologies Values in parenthesis are estimated tialf-times of disassociation of a molecule containing this sequence using a subsequence of 10 for scoring (33) . The score for 109 ranges from 20 to 60 for different subsequences. The score for 106 changes from 50.0 for a subsequence of 8 to 80.0 for a subsequence of 9. The score for 711 does not go above 1.0 for subsequences of 8 or 9.
Rockville, MD) supplemented with 5% heat-inactivated FCS, L-glutamlne, penicillin (100 lU/ml) and streptomycin (100 ng/ml).
Cytokine production
Supematants were collected from the co-cultures of splenocytes or purified T lymphocytes 72 h after in vitro stimulation with carbohydrate, peptides and media. The concentrations of IL-4, IL-10 and IFN-y were measured by quantitative capture ELISA (PharMingen), according to the manufacturer's instructions.
CTL assay
Cytotoxic activity was measured by a 5 (P815 cells)-or 16 (Meth A cells)-h ^''
Cr-release assay, as described elsewhere (30, 31) . Briefly, effector cells were stimulated for 5 days in the presence of stimulator cells and 10% RAT-T-STIM without concanavalin A (Becton Dickinson Labware, Bedford, MA). Peptide-pulsed murine mastocytoma P815 cells were used as stimulators (10:1 effector:stimulator ratio) and targets in 5-h assay, as described before (30, 32) . Meth A cells were treated with MMC and used as stimulator in 300:1 effector:stimulator ratio. For MMC treatment, 1x10^ cells were treated in 1 ml of RPMI media supplemented with 10% FBS, with 100 ng MMC at 37°C for 40 min. Cells were washed 3 times after treatment.
Untreated Meth A cells were used as target cells. All target cells were labeled with 100 (iCi/m! Na2^''Cr04 and mixed with effector cells at E:T ratios ranging from 50:1 to 3:1. Maximum and minimum (spontaneous) releases were determined by lysis of target cells in 5% Triton X-100 and medium respectively. Lysis was calculated as [(experimental -spontaneous)/ (maximum -spontaneous)] x 100. An assay was not considered valid if the values for the 'spontaneous release' count were >20% (for 5-h assay) or 30% (for 16-h assay) of the 'maximum release'. To calculate specific lysis of targets, the percent lysis of non-specific targets (P815 cells) was subtracted from the percent lysis of specific targets (peptidepulsed P815 cells).
Statistical analysis
Data were analyzed by using Student's f-test. Values of P < 0.05 were considered statistically significant. All experiments were performed at least 3 times. 
Results
Peptide immunization primes for a specific cellular response
To facilitate a cellular response, we had designed peptide 106 (Table 1) with the potential to bind to H2-K'* and l-A''. MHC binding prediction calculations identifies an H2-K^ and 1-A<^ binding motif centered on the RYDIYWRYDI sequence of the 106 peptide (Table 1) (33) . Furthermore, the WRYDI sequence tract of the 106 peptide also displays similarity to a peptide sequence tract (DIYRW) identified in a peptide that binds to GDI (34) , which may play a role in activating NK T cells.
To analyze the cellular response upon peptide 106 immunization, BALB/c mice were immunized with the mimeotope and the proliferative response of isolated splenocytes to the peptides 106, 711 (Table 1) as MAP forms, as well as OVA (as an additional control) was determined. As expected, in vivo primed splenocytes from 106 peptide-immunized animals were specifically activated by peptide 106, and not control peptides, in a statistically significant concentrationdependent manner (Fig. 1) . Peptide 106 did not stimulate splenocytes from naive animals or from animals immunized with QS-21 alone (data not shown). These results indicate SSn , ■P''°L^?^^^'°" '® ^^'^ dependent, and is blocked by anti-MHC c ass II and I antibodies. Mice were immunized with 106 peptide as explained in the legend to Rg. 1 and splenocytes were collected 7 days after the last immunization. (A) Proliferation assay was perfom^ed on splenocytes and purified T lymphocytes (with or without T^nLln^'^T^c'^^rBl ^'^ 2 peptide concentration of sotypes were used for blocking of proliferation of splenocytes. sotype controls acted very similarly, so just one of those is presented r ^P'fr'^y?®^ *e^s stimulated using peptides 106, 711 and OVA ivn^rl if ^li^' ^""^ "'^-"^ '®^e'^ ^e^e quantified. All resutts are expressed as the mean * SEM of four independent experiments with triplicate samplings. *P < 0.05; "P < 0.01. that immunization with peptide 106 mediates a peptidespecific cellular response.
Anti-MHC class II and I inhibit proliferative response
A standard cell proliferation was performed with purified T lymphocytes alone and after addition of MMC-inactivated APC (Fig. 2A) . The results indicate that proliferation is APC dependent. Proliferation of the T lymphocytes was not observed in the absence of APC. Proliferation was inhibited by the addition of specific anti-l-A«' anti-class II and to a lesser extent with anti-class I antibodies (Fig. 2B) . The addition of anti-CDl antibody Inhibited proliferation to almost the same extent as addition of anti-class I antibody. Therefore, the 106 peptide might be presented in multiple ways toT cellshowever, MHC class ll-dependent presentation appears to be the major pathway (60% inhibition by anti-class II antibody)
For analysis of cytokine profiles, plates for proliferation were doubled and the supernatant of duplicated plates were harvested after 72 h of in vitro activation. IFN-y production was found to be peptide specific (Fig. 2C) , with no detectable presence of IL-4 or IL-10 (data not shown). The sensitivity for IL-4 and IL-10 detection was 7.8 and 31.3 pg/ml respectively Taken together, these results demonstrate that 106-MAPpeptide immunization along with QS-21 potentially activates lymphocyte populations with a predominant T^l phenotype.
Activation down-modulates L-selectin
We examined L-selectin expression on CD4+ T cells L-selectin is preferentially expressed on T^l over \2 cells (23) . The activation of T cells through the TCR results in the differential regulation of L-selectin (24) . Using FACS analysis we studied the expression of L-selectin on CD4+ T cells frorri naive and peptide-immunized animals before and after in vitro stimulation with peptide 106 to assess activation (Fig. 3) in keeping with other studies, a population of cells from peptide 106-immunized mice remained clearly L-selectin+ after in vitro stimulation (24) . The demonstrated presence and loss of L-selectin on the surface of CD4+ T cells occurring upon stimulation to the 106 peptide further confirms a Thi nature for these cells. It was observed that sLex could activate these cells as effectively as peptide 106 as assessed by L-selectin loss (Fig. 3) .
Carbohydrate stimulates proliferation of 106 peptide-primed splenocytes
In separate experiments, isolated splenocytes were incubated with sLex, Lex and LeY (Fig 4A) . sLex and Lex. but not LeY stimulated a proliferative response with splenocytes from 106-immunized animals. Splenocytes from mice immunized with the carbohydrate antigens sLex or LeY did not proliferate upon incubation with peptide 106, LeY, sLex or Lex (Fig 4B  and C) . This result suggests that priming with the peptide mimeotope leads to a specific carbohydrate cross-reactive cellular response.
/WHC class II molecule is involved in proliferation of peptideprimed T lymphocytes by carbohydrate
sLex-stimuiated proliferation of peptide-primed T lymphocytes was inhibited by the l-A^f-specific anti-MHC class II antibody, suggesting a role played by the class II molecule in the crossreactivity between the carbohydrate antigen and peptideprimed responder cells and APC (Fig. 5A) . The specificity of the antibody for l-A^ has been assessed by others, indicating specific MHC class II inhibition of proliferation (35) (36) (37) . IFN-v production for sLex activation was detected (Fig. 5B) . As in the peptide case, we could not detect any IL-4 and IL-10 production after activation. This production was specific for peptide-immunized mice compared with T lymphocytes denved from mice immunized with QS-21 alone or from naive animals. 
Peptide boost of Meth A cell-primed animals enhances CTL activity against Meth A cells
In vitro stimulated effector cells from peptide 106-injected animals showed high specific lysis against peptide-pulsed P815 cells, confirming the peptlde's ability to function as a MHC class 1 target (Fig. 6A) . As expected, cytotoxicity was reduced in experiments in which CDS"^ cells were depleted. When Meth A cells were used as stimulators and targets, we observed moderate cell l<iliing (Fig. 6B) . In contrast, no significant cytotoxicity was detected on the P815 cells, used as a negative control. P815 cells did not express sLex, as assessed by FACS using the mAb FH-6 (data not shown) nor did serum to peptide 106 bind to P815 cells, also assessed by FACS (data not shown). We did not detect any significant increase in lysis of peptide pulsed We obsen/ed a cytotoxic enhancement effect upon immunization with peptide 106 using effector cells from Meth A-immunized mice compared with those from Meth A-primed/ peptide-boosted mice (Fig. 7B) . The level of CTL was consistent with those observed in similar studies (31, 32) . A clear increase in lysis was observed in the cell-primed/peptideboosted animals compared to mice immunized with Meth A cells only. We did not detect any cytotoxicity using re- subsets that are involved in cytotoxicity targeting Meth A cells (31, 32) . However, In the case of peptide mimetic boost of Meth A cell-immunized animals, MHC class l-restricted/CD8'^-dependent T cells showed a predominant role in the CTL response. Our results further indicate that L-selectin may participate in the lysis process as described previously (14) . frc^^TmTe^'lact' ""^^ ^ '" ^°" ''''' replications and are representative of three independent experiments using pooled cells cpfnt?"! "'®'® ^'^° "®®.^ ^ ^'9®^® ^^ "° significant lysis (6%) was detected SplSes^wTrfcSrSyfaft^^^^^ "^'^' '" ' ™"'^ ^"'^ '^^ '°°^^' -"^ ^^th A 106 petide/QS-21 or QS-21 ^one. "ND, not determined.
««^=tors against P815 cells as targets or of na'^e
With naive mice and QS-21-immunized mice, as before, we did not detect any significant lysis.
Discussion
We had previously demonstrated that immunization with a multivalent, repetitive peptide mimetic of sLex (peptide 106) induced an anti-sLex cross-reactive antibody response to Meth A tumor cells (19) . Antibody responses to sLex can mediate complement-dependent killing of sLex-expressing tumor cells inhibiting the establishment and growth of metastatic colonies as observed in several animal models (12, 19, 38) .
Meth A tumor growth inhibition upon immunization with attenuated Meth A cells is reported to be dependent on CD4+ and CD8+ T cell responses to undefined glycoproteins (31,32.39-41) . Commitment of lymphocytes to the Thi and to CD8+ T cell phenotypes as characterized by the expression of IFN-Y, may be critically involved in tumor rejection (42, 43) . However, the expression of L-selectin on these cell types may also lend to CTL activity (14) . IFN-y and lymphocytes work together to find and eliminate tumor cells (44) . As the adjuvant QS-21 promotes the 1^1 phenotype, which expresses Lselectin, and peptide 106 can induce a Thi-associated humoral response, we examined if immunization with peptide 106 along with QS-21 could augment cellular responses to sLexexpressing Meth A tumor cells.
Immunization with the mimeotope led to peptide-specific cell proliferation that was concentration dependent (Hg. 1). As expected, cell proliferation was primarily MHC class 11 dependent as determined by inhibition with respective anti-MHC antibody (Fig. 2) . Cell stimulation with peptide 106 triggered IFN-y release, suggesting that peptide immunization with QS-21 as expected polarized the T^l subset (Fig. 2C) . Consistent with previous studies we observed L-selectin loss on CD4+ T lymphocytes upon peptide stimulation, but also saw this loss upon stimulation with sLex (Hg. 3). The proliferative response was peptide, sLex and Lex specific since LeY did not exhibit any cellular responses nor did splenocytes from sLex-and LeY-immunized animals responded to peptide 106, sLex or Lex antigens (Rg. 4).
We observed that sLex activated T lymphocytes from 106 immunized animals to proliferate and secrete IFN-y (Fig. 5 ) Cell activation by sLex was inhibited by anti-MHC class li antibody addition, suggesting a possible role for this molecule in the presentation process (Fig. 5B) . In vivo stimulated effector cells from peptide 106 immunization displayed cytotoxicity directed toward peptide 106-pulsed MHC class 1+ class II-P815 target cells, further verifying a role for CD8" T cell reactivity with peptide 106 (Fig. 6) . While Meth A cell pnming and boosting can lead to CTL activity against Meth A cells, peptide boosting increased the level of cytotoxicity against Meth A cells to a statistically significant level as compared with cytotoxicity against P815 cells as control target (Fig. 7 and Table 2 ), indicating a cross-reactive nature between peptide and tumor specif ic CTL responses.
CTL activity was inhibited by the addition of either anticlass I or anti-L-selectin antibody (Table 2 ). However, we could not block CTL activity by the sLex-reactive antibody FH-6 (data not shown). It is possible that FH-6 binds to a subtype of sLex carbohydrate epitopes that do not always function as ligands for L-selectin just like it defines a subset that does not bind to E-selectin (2) . This is also similar to that found for the antibody MECA 79 which binds to a subset of sulfated sLex different than that of L-selectin (45). L-selectin IS known to bind to a variety of carbohydrates expressed on glycoproteins (46, 47) . It is possible that L-selectin functions as an auxiliary molecule (48) and by itself is not sufficient to mediate CTL killing, but requires engagement of antigenspecific TCP (14) . NK cells, on the other hand, also express L-selectin and other lectin-type molecules, and NK cells appear to mediate cytolysis of tumor cells that express high levels of sLex (18) . However, direct evidence that fuscosylated selectin ligands play a role in tumor rejection is still lacking
The activation of cross-reactive T cells has been described in many systems. What is the specificity of the CD8+ T cells targeting Meth A? Meth A cell-primed T cells maybe glycopeptide/glycoprotein specific (32), which are cross-reactive with peptide 106. as glycopeptides are known to activate T cells that recognize the carbohydrate moiety on MHC-associated glycopeptides (49) (50) (51) (52) (53) (54) (55) . Direct interaction of the TCP with the carbohydrate (27.56) is dependent on the chemical structure of the glycan as well as its position within a peptide. Glycopeptides with GlcNAc residues known to associate with class I (25) also induce CTL responses (26) . T ceils primed to glycopeptides carrying more complex saccharide antigens sometimes show a complicated pattern of cross-responses to glycopeptides with simpler glycan moieties (51) . It argues that the presentation of carbohydrate antigens on Meth A should be more thoroughly characterized in terms of the structure of glycopeptides, glycoshingollpids, etc., which is beyond the scope of the present paper.
Proliferation by sLex and Lex is tougher to reconcile. Carbohydrate antigens have been proposed to associate with MHC directly (57); however, this type of association has not yet been confirmed in our system. It is possible that proliferation is associated with some yet undefined superantigen-like association as we observed up-regulation of GDI 5s on sLex activated T cells (data not shown). Superantigens but not mitogens are capable of inducing up-regulation of E-selectin ligands on human T lymphocytes (58) . Likewise, bacterial polysaccharides and mimicking peptides with a distinct charge motif involving Lys and Asp residues have been shown to activate T lymphocytes and that this activity confers immunity to a distinct pathologic response to bacterial Infection (59) . Peptide 106 has a Arg residue homologous to Lys, with the Asp residues identical to peptides that induce crossreactive cellular responses In bacterial studies (59) . The molecular details of how this occurs are not as yet known. Further analysis of binding affinities of peptide and carbohydrate with l-A"^ will be illuminating. However, immunization with sLex did not induce T lymphocytes that reacted with peptide 106 nor itself, an effect of sLex being a T cell-independent antigen.
Immunization with peptide 106 induces cellular responses that are not achievable by immunization with carbohydrate alone. Nevertheless, the induction of optimal systemic antitumor immunity involves the priming of both CD4+ and CDS"^ T cells specific for tumor-associated antigens. Although cellular responses generated by the peptide mimeotope may enhance CTL induction, vaccination with peptide alone appears not to be completely sufficient in the effector phase when challenged with a very high tumor burden (19) . Our CTL data using effectors from peptide-only-immunized mice on Meth A cells as targets (Fig. 6B ) confirm this fact with marginal CTL activity observed. Consequently, we did not observe complete tumor protection in our previous study (19) .
Our results are very narrow with regard to the breadth of carbohydrate directed cellular responses. However, constituents of sLex and sLea are proposed to be influential to the metastatic properties of a variety of human tumor cells. Consequently, further efforts to optimize and isolate the carbohydrate moieties associated with presented glycopeptides may facilitate vaccine applications for eradication of metastatic lesions by both antibody-dependent lysis and cellular responses. This possibility has yet to be proved with the appropriate models but suggests that for certain carbohydrate antigens, peptide mimetics might augment cellular responses other than delayed-type hypersensitivity like responses (60) in future vaccine applications.
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